证券代码：300244 证券简称：迪安诊断 公告编号：2025-002 迪安诊断技术集团股份有限公司 2024年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间 2024 年 01 月 01 日—2024 年 12 月 31 日 | 项 目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | 亏损：27,000 | 万元–37,000 万元 | 盈利：30,746.11 | 万元 | | 扣除非经常性损 益后的净利润 | 亏损：30,000 | 万元–40,000 万元 | 盈利：29,475.47 | 万元 | 二、与会计师事务所沟通情况 公司已就本次业绩预告有关事项与会计师事务所进行预沟通，公司与会计师 事务所在业绩预告相关财务数据方面不存在分歧。 本次业绩预告相关财务数据未经注册会计师审计。 三、业绩变动原因说明 1、报告期，公司经营主基调是"内紧外冲、韧性成长"。对内，加大推动 供应链降本高效化、人力效能最大化、 ...

证券研究报告 2024 年 11 月 06 日 湘财证券研究所 公司研究 迪安诊断（300244）业绩点评 % 1 个月 3 个月 12 个月 相对收益 -5 -6 -52 绝对收益 -4 12 -39 注：相对收益与沪深 300 相比 前三季度业绩承压，经营现金流明显好转 核心要点： 前三季度营收同比下降 10.05%，扣非归母净利同比下降 72.18% 近期，公司发布了 2024 年三季报，前三季度公司实现营业收入 92.58 亿元， 同比下降 10.05%，归母净利润 1.31 亿元，同比下降 75.35%，扣非净利润 1.34 亿元，同比下降 72.18%。 单季度看，2024Q3 实现营业收入 30.40 亿元，同比下降 11.89%，归母净利 润 0.59 亿元，同比下降 23.81%，扣非净利润 0.59 亿元，同比下降 60.76%。 现金流有所改善，销售承压下毛利率及净利率下降明显 2024 年前三季度公司销售费用率 9.47%，同比上升 0.85 pct，管理费用率为 5.91%，同比下降 0.41 pct，财务费用率 1.64%，同比下降 0.01 pct，研发费 用率 2.43%，同比 ...

迪安诊断（ [Table_StockNameRptType] 300244） 公司点评 现金流改善，ICL 出海打开新局面 | --- | --- | --- | --- | |-------------------------------------------------------------------------------|------------------------------------------------------------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

迪安诊断（300244.SZ） 医疗服务 证券研究报告/公司点评报告 2024 年 10 月 24 日 ICL 基本面底部确立，盈利能力、经营性现金流有望持续改善 | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

公司点评报告 ·医药行业 医检业务持续承压,精益管理助益未来成长 2024 年三季报业绩点评 2024年10月 24日 | --- | --- | --- | --- | |-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Revenue for the third quarter was RMB 3.04 billion, a decrease of 11.89% year-over-year[2] - Net profit attributable to shareholders was RMB 59.11 million, down 23.81% year-over-year[2] - Operating cash flow for the first nine months was RMB 54.2 million, a significant decrease of 85.22% year-over-year[2] - Total assets decreased by 4.81% to RMB 17.08 billion compared to the end of the previous year[2] - Net profit for the quarter decreased to 302.68 million yuan, down from 791.43 million yuan in the same period last year[18] - Sales revenue for the quarter was 9.42 billion yuan, compared to 11.78 billion yuan in the previous year[19] - Operating cash flow for the quarter was 54.20 million yuan, a significant drop from 366.81 million yuan in the same period last year[20] - The company's operating income for the current period was 9,258,110,867.57 yuan, compared to 10,292,194,930.88 yuan in the same period last year[17] - The company's operating costs for the current period were 8,491,254,006.48 yuan, compared to 8,977,566,104.97 yuan in the same period last year[17] Revenue Breakdown - Diagnostic services revenue reached RMB 1.155 billion, with ICL business contributing RMB 1.048 billion[5] - Channel product business revenue was RMB 1.912 billion, while proprietary product revenue was RMB 86 million[5] Expansion and Investments - The company added 4 new precision centers in Q3, bringing the total to 84, with 52 already profitable[6] - International expansion continued with the opening of a testing laboratory in Vietnam[6] - Long-term equity investments increased by 46.71% to RMB 983.57 million due to the acquisition of equity in an associate[5] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 39,463[7] - Chen Haibin, a domestic natural person, holds 26.31% of the shares, totaling 164,438,933 shares, with 123,329,200 shares under restricted sale[7] - Hong Kong Securities Clearing Corporation, an overseas legal entity, holds 3.90% of the shares, totaling 24,355,573 shares[7] - China Bank Limited - Huabao CSI Medical ETF holds 2.73% of the shares, totaling 17,079,326 shares[7] - Hangzhou Dian Holding Co., Ltd., a domestic non-state-owned legal entity, holds 1.70% of the shares, totaling 10,636,390 shares[7] - Xu Min, a domestic natural person, holds 1.60% of the shares, totaling 10,007,933 shares[7] - Morgan Stanley & Co. International PLC, an overseas legal entity, holds 0.78% of the shares, totaling 4,854,440 shares[7] - BNP Paribas - Own Funds, an overseas legal entity, holds 0.77% of the shares, totaling 4,793,600 shares[7] - Cai Ziwei, a domestic natural person, holds 0.74% of the shares, totaling 4,596,900 shares[7] Share Repurchase and Capital Reduction - As of September 30, 2024, the company has repurchased 13,406,000 shares, accounting for 2.14% of the total shares, with a total transaction amount of RMB 193,590,266[12] - The company plans to change the use of repurchased shares from "employee stock ownership plan or equity incentive" to "cancellation and corresponding reduction of registered capital," resulting in the cancellation of 1,918,600 shares and a reduction in total shares from 626,898,036 to 624,979,436[13] Financial Position - As of September 30, 2024, the company's monetary funds decreased to 1,370,982,095.00 yuan from 2,973,332,466.18 yuan at the beginning of the period[14] - The company's accounts receivable increased to 8,366,381,925.24 yuan from 8,054,200,551.87 yuan at the beginning of the period[15] - The company's inventory increased to 1,797,893,772.68 yuan from 1,508,948,754.81 yuan at the beginning of the period[15] - The company's total assets decreased to 17,075,684,838.18 yuan from 17,939,311,256.63 yuan at the beginning of the period[15] - The company's total liabilities decreased to 7,597,898,943.63 yuan from 8,034,531,783.60 yuan at the beginning of the period[16] Expenses and Income - R&D expenses decreased to 225.28 million yuan from 320.48 million yuan in the previous year[18] - Management expenses were reduced to 547.06 million yuan from 650.88 million yuan in the same period last year[18] - Investment income for the quarter was 9.18 million yuan, up from 632,086.78 yuan in the previous year[18] - Income tax expenses decreased by 47.18% to RMB 121.49 million due to lower profit[5] Cash Flow - Cash received from selling goods and providing services was 9.42 billion yuan, down from 11.78 billion yuan in the same period last year[19] - Cash paid for goods and services was 6.43 billion yuan, compared to 7.54 billion yuan in the previous year[20] - Cash paid to employees decreased to 1.62 billion yuan from 2.03 billion yuan in the same period last year[20] - Cash received from investment activities was 569.13 million yuan, down from 948.12 million yuan in the previous year[20] - Net cash flow from investment activities was -622.52 million yuan, a decrease of 85.5% compared to the previous period's -335.63 million yuan[21] - Cash received from investments was 53.12 million yuan, a decrease of 3.8% compared to the previous period's 55.20 million yuan[21] - Cash received from borrowings was 1.43 billion yuan, an increase of 37.5% compared to the previous period's 1.04 billion yuan[21] - Total cash inflow from financing activities was 1.66 billion yuan, an increase of 17.9% compared to the previous period's 1.41 billion yuan[21] - Cash paid for debt repayment was 1.53 billion yuan, a decrease of 41.5% compared to the previous period's 2.62 billion yuan[21] - Cash paid for dividends, profits, or interest payments was 654.08 million yuan, an increase of 62.5% compared to the previous period's 402.56 million yuan[21] - Total cash outflow from financing activities was 2.68 billion yuan, a decrease of 20.3% compared to the previous period's 3.36 billion yuan[21] - Net cash flow from financing activities was -1.02 billion yuan, an improvement of 47.7% compared to the previous period's -1.96 billion yuan[21] - Net increase in cash and cash equivalents was -1.60 billion yuan, an improvement of 17.1% compared to the previous period's -1.93 billion yuan[21] - Ending balance of cash and cash equivalents was 1.35 billion yuan, a decrease of 39.1% compared to the previous period's 2.22 billion yuan[21] Shareholder Pledges - The company's actual controller, Mr. Chen Haibin, and his concerted parties have pledged a cumulative 18.40% of the company's total shares, accounting for 65.69% of their holdings as of September 30, 2024[13]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 12.80 RMB [2][5] Core Views - The company's performance is under short-term pressure due to factors such as impairment provisions In H1 2024, the company achieved revenue of 6.22 billion RMB, a year-on-year decrease of 9.12% The diagnostic service business generated 2.36 billion RMB, down 13.4% year-on-year, while the diagnostic product business generated 4.09 billion RMB, down 5.9% year-on-year The net profit attributable to the parent company was 70 million RMB, a year-on-year decrease of 84.2%, mainly due to a decline in the gross profit margin of the diagnostic service business [1] - The company's ICL business achieved revenue of 2.19 billion RMB in H1 2024, a year-on-year increase of 6.3% The company launched 176 new testing projects, with significant revenue growth in infectious diseases (+93%), hematology (+84%), and neuroimmunology (+53%) The company also added 41 new cooperative laboratories and 10 precision centers, with revenue increases of 11% and 35% respectively [1] - In the diagnostic product business, the company obtained 5 Class II certificates and 18 Class I certificates in H1 2024 Subsidiary "Kailai Spectrum" obtained 6 Class I reagent registration certificates, and subsidiary "Dian Diagnostics" received approval for a Class III registration certificate for a gene detection kit [1] Financial Forecasts - The report adjusts the EPS forecasts for 2024-2026 to 0.64/1.06/1.29 RMB (previously 1.25/1.58/1.99 RMB) based on the 2024 semi-annual report [2] - Revenue is expected to be 12.673 billion RMB in 2024, with a year-on-year decrease of 5.5%, and is projected to grow by 7.1% and 7.2% in 2025 and 2026 respectively [4] - The net profit attributable to the parent company is forecasted to be 398 million RMB in 2024, with a year-on-year increase of 29.6%, and is expected to grow by 66.2% and 21.7% in 2025 and 2026 respectively [4] Valuation and Market Performance - The company's stock price was 9.9 RMB as of September 6, 2024, with a 52-week high/low of 27.85/9.75 RMB [5] - The company's market capitalization is 6.187 billion RMB, with a total share capital of 624.98 million shares and a circulating A-share capital of 501.48 million shares [5] - The company's PE ratio is 15.5 for 2024, with a PB ratio of 0.8 [4]

迪安诊断（ [Table_StockNameRptType] 300244） 公司点评 二季度收入环比改善，减值影响利润 | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

请阅读最后一页免责声明及信息披露 http://www.cindasc.com 1 | --- | --- | |-------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

多重扰动下常规 ICL 增长稳健，看好下半年政策缓和下业绩回升 迪安诊断（300244）/医疗器械 证券研究报告/公司点评 2024 年 8 月 26 日 [Table_Industry] | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------------------------------------------------------------------------------------------------------- ...